Fifty Years

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

64x Bio is a biotechnology company based in San Francisco, California, founded in 2017 by Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver. The company specializes in designing microorganisms with enhanced properties to facilitate advanced applications in biomanufacturing, bioremediation, and health. By creating cells tailored for specific purposes, 64x Bio aims to enable innovative solutions that were previously unattainable in these fields.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Gordian Biotechnology, Inc. is focused on developing a screening platform for gene therapy aimed at treating age-related diseases. Established in 2018 and headquartered in San Francisco, California, the company is pioneering a novel discovery platform designed to enhance drug development for complex ailments associated with aging.

Cofactor Genomics is a biotechnology company focused on advancing precision medicine through predictive immune modeling. By leveraging its expertise in RNA sequencing and expression analysis, Cofactor aims to move beyond traditional single-analyte biomarkers to develop multidimensional biomarkers that enhance clinical insights. The company's platform examines RNA biomarkers linked to responses to targeted therapeutics, allowing biotechnology firms to create clinical diagnostic assays for oncology, immunology, and neurodegenerative diseases. With a CAP-certified clinical RNA sequencing laboratory and a suite of molecular, informatic, and database tools, Cofactor supports its partners in conducting more efficient and successful clinical trials, ultimately facilitating the commercialization of innovative therapeutic solutions.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Clear Genetics, Inc. is a digital health company that specializes in providing genetic counseling services to women, healthcare providers, and health systems. Founded in 2016 and based in San Francisco, California, the company offers a web application called Clearancy, which delivers personalized genetic information for patients undergoing genetic testing and their medical practitioners. Clear Genetics focuses on various medical specialties, including prenatal care, cardiology, carrier screening, hereditary cancer, and pediatrics. By partnering with health systems, laboratories, and academic institutions, Clear Genetics aims to enhance patient access to genetic counseling and testing, facilitating the thoughtful integration of genetics into routine patient care. As of November 2019, Clear Genetics operates as a subsidiary of Invitae Corporation.

Cofactor Genomics is a biotechnology company focused on advancing precision medicine through predictive immune modeling. By leveraging its expertise in RNA sequencing and expression analysis, Cofactor aims to move beyond traditional single-analyte biomarkers to develop multidimensional biomarkers that enhance clinical insights. The company's platform examines RNA biomarkers linked to responses to targeted therapeutics, allowing biotechnology firms to create clinical diagnostic assays for oncology, immunology, and neurodegenerative diseases. With a CAP-certified clinical RNA sequencing laboratory and a suite of molecular, informatic, and database tools, Cofactor supports its partners in conducting more efficient and successful clinical trials, ultimately facilitating the commercialization of innovative therapeutic solutions.